Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Pharmaxis’s Bronchitol Wins U.K. Cost Agency’s Backing

Pharmaxis Ltd.’s Bronchitol won the backing of the U.K.’s health-cost regulator for use in some patients with cystic fibrosis, a rare genetic illness.

The drug may be used for adults who can’t use other treatments and whose lung function is rapidly declining, the London-based National Institute for Health and Clinical Excellence, known as NICE, said in a statement on the final draft recommendations. The agency reversed a decision from June, in which the agency said it couldn’t back the drug because of “gaps and uncertainties in the evidence on its effectiveness.”

The agency advises the National Health Service on which treatments represent value for money. Final guidance on Bronchitol, also known as mannitol, is expected to be published in November, NICE said.

“Following the helpful responses received during consultation on the draft guidance, the committee concluded that mannitol was a good use of NHS resources when treatment was offered to those who cannot use hypertonic saline or rhDNase and whose lung function is rapidly declining,” the agency said.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.